Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda

Journal of Medical Virology

Volumn 79, Issue 12, 2007, Pages 1797-1801

  Pirillo, Maria F ^a   Bassani, Luciana ^a   Germinario, Elena A P ^a   Mancini, Maria Grazia ^a   Vyankandondera, Joseph ^b   Okong, Pius ^c   Vella, Stefano ^a   Giuliano, Marina ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Centre Hospitalier Universitaire de Kigali   (Rwanda)

^c St Francis Hospital Uganda   (Uganda)

Author keywords

Co infection; HBV; HCV; HIV; Pregnancy; Rwanda; Uganda

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; VIRUS DNA; VIRUS RNA;

ADULT; ANTIBODY DETECTION; ARTICLE; COMORBIDITY; DISEASE TRANSMISSION; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; PREGNANCY; RWANDA; SEROPREVALENCE; UGANDA; VIRUS HEPATITIS; VIRUS INFECTION; VIRUS TRANSMISSION;

FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV INFECTIONS; HUMANS; PREGNANCY; RETROSPECTIVE STUDIES; RWANDA; SEROEPIDEMIOLOGIC STUDIES; UGANDA; VIRAL LOAD;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 35549013639     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21007     Document Type: Article

References (21)

1. Alter MJ. 2006. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44:S6-S9.
2. Baylor MS, Johann-Liang R. 2004. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 35:538-539.
3. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. 2001. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 33:562-569.
4. Guitton E, Montastruc JL, Lapeyre-Mestre M. French Network of Pharmacovigilance Centre. 2006. Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. Eur J Clin Pharmacol 62:243-249.
5. Hladik W, Kataaha P, Mermin J, Purdy M, Otekat G, Lackritz E, Alter MJ, Downing R. 2006. Prevalence and screening costs of hepatitis C virus among Ugandan blood donors. Trop Med Int Health 11:951-954.
6. Joint United Nations Program on HIV/AIDS and World Health Organization. 2006. AIDS Epidemic Update. Geneva, Switzerland: World Health Organization Available at: http:www.unaids.org
7. Madhava V, Burgess C, Drucker E. 2002. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2:293-302.
8. Matsumoto C, Nishioka K, Oguchi T, Mitsunaga S, Nojiri N, Tadokoro K, Juji T. 1997. Detection and quantitation of HBV DNA by seminested PCR in donated blood: Comparison with HBV serological markers. J Virol Methods 66:61-69.
9. Msuya SE, Mbizvo E, Hussain A, Sam NE, Stray-Pedersen B. 2006. Seroprevalence of hepatitis B and C viruses among women of child-bearing age in Moshi Urban. Tanzania. East Afr Med J 83:91-94.
10. Nakwagala FN, Kagimu MM. 2002. Hepatitis B virus and HIV infections among patients in Mulago hospital. East Afr Med J 79:68-72.
11. Ndjomou J, Kupfer B, Kochan B, Zekeng L, Kaptue L, Matz B. 2002. Hepatitis C virus infection and genotypes among human immunodeficiency virus high-risk groups in Cameroon. J Med Virol 66:179-186.
12. Pido B, Kagimu M. 2005. Prevalence of hepatitis B virus (HBV) infection among Makerere University medical students. Afr Health Sci 5:93-98.
13. Ren FR, Lu QS, Zhuang H, Li JJ, Gong XY, Gao GJ, Liu CL, Wang JX, Yao FZ, Zheng YR, Zhu FM, Tiemuer MHL, Bai XH, Shan H. 2005. Significance of the signal-to-cutoff ratios of anti-hepatitis C virus enzyme immunoassay in screening of Chinese blood donors. Transfusion 45:1816-1822.
14. Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, Leroy V, Dabis F, Rouzioux C. for ANRS 1236 DITRAME- B&C Study Group. 2004. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study. J Med Virol 74:34-40.
15. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F. 2005. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 191:825-829.
16. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. 2000. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283:74-80.
17. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. 2002. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 36:512-513.
18. Sutcliffe S, Taha TE, Kumwenda NI, Taylor E, Liomba GN. 2002. HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi. J Acquir Immune Defic Syndr 31:90-97.
19. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL. 2002. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360:1921-1926.
20. Vyankandondera J, Luchters S, Hassink E, Pakker N, Mmiro F, Okong P, Kituuka P, Ndugwa C, Muganga N, Beretta A, Imperiale M, Loeliger E, Giuliano M, Lange J. 2003. Reducing risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA study) [abstract # LB7]. Paris: Presented at: 2nd IAS Conference on HIV. Pathogenesis and Treatment
21. World Health Organization. 2006. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: Towards universal access. Geneva, Switzerland: World Health Organization.